LETTER TO THE EDITOR

Genomics and epidemiology for gastric adenocarcinomas (GE4GAC): a Brazilian initiative to study gastric cancer

GE4GAC group, Thais F. Bartelli1, Lais L. Senda de Abrantes2, Helano C. Freitas1,18, Andrew M. Thomas1,3,4, Jordana M. Silva1, Gabriela E. Albuquerque1, Luiza F. Araújo1, Gabriela P. Branco1, Maria G. de Amorim1, Marianna S. Serpa1, Isabella K. T. M. Takenaka1, Deborah T. Souza1, Lucas O. Monção1, Bruno S. Moda5, Renan Valieri5, Alexandre Defelicibus5, Rodrigo Borges5, Rodrigo D. Drummond5, Francisco I. A. Alves6, Monize N. P. Santos5, Irina G. Bobrovnitchaia5, Eran Elhaik7, Luiz G. V. Coelho8, André Khayat9, Samia Demachki10, Paulo P. Assumpção10, Karina M. Santiago11, Giovana T. Torrezan11, Dirce M. Carraro11, Stela V. Peres12, Vinicius F. Calsavara12, Rommel Burbano13,10, Calebe R. Nóbrega12, Graziela P. P. Baladão12, Ana C. C. Pereira12, Camila M. Gatti12, Marcela A. Fagundes10, Marília S. Araújo10, Tayana V. Miranda9, Monica S. Barbosa14, Daniela M. M. Cardoso14, Lilian C. Carneiro14, Alexandre M. Brito15, Amanda F. P. L. Ramos14, Lucas L. Silva14, Jaqueline C. Pontes14, Tatiane Tiengo12, Paola E. Arantes12, Vilma Santana16, Milena Cordeiro16, Rosane O. Sant’Ana17, Hanna B. Andrade17, Ana K. M. Anaissi10, Sara V. Sampaio17, Emne A. Abdallah7, Ludmilla T. D. Chinen2, Alexcia C. Braun2, Bianca C. T. Flores2, Celso A. L. Mello18, Laura C. L. Claro19, Claudia Z. Sztokfisz20, Carlos C. Altamirano21, David R. F. Carter22, Victor H. F. Jesus18, Rachel Rielhmann18, Tiago Medina23, Kenneth J. Gollob23, Vilma R. Martins24, João C. Setúbal4, Adriane G. Pelosi20, Felipe J. Coimbra25, Wilson L. Costa-Jr25, Israel T. Silva5, Diana N. Nunes1, Maria P. Curado12 and Emmanuel Dias-Neto1*

Abstract

Gastric cancer (GC) is the fifth most common type of cancer worldwide with high incidences in Asia, Central, and South American countries. This patchy distribution means that GC studies are neglected by large research centers from developed countries. The need for further understanding of this complex disease, including the local importance of epidemiological factors and the rich ancestral admixture found in Brazil, stimulated the implementation of the GE4GAC project. GE4GAC aims to embrace epidemiological, clinical, molecular and microbiological data from Brazilian controls and patients with malignant and pre-malignant gastric disease. In this letter, we summarize the main goals of the project, including subject and sample accrual and current findings.

Keywords: Gastric cancer, Epidemiology, Microbiome, Whole exome sequencing, Genomic ancestry, Liquid biopsy, Hereditary gastric cancer, Database

Opt The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
The global distribution of gastric cancer (GC) is heterogeneous, a consequence of worldwide socio-economic disparities as well as of the human-diversity in terms of ancestry and cultural habits, including diet. This heterogeneity is not limited to global incidence but also embraces treatment response, clinical and pathological presentation, and the mutational landscape. This leads to frail translation of the still limited findings from US/Europe/Asia to other countries, including highly admixed and least-studied populations. In an attempt to reduce the GC knowledge-gap, the GE4GAC project, supported by FAPESP (14/26897–0), was implemented in 2016 at the A.C.Camargo Cancer Center (ACCCC) in São Paulo, Brazil. Collaborations are underway with the National Cancer Institute (NIH, USA); Instituto Nacional de Enfermedades Neoplásicas (Peru) and both the VOGAS (www.vogas.eu) and the StoP (www.stop-project.org) consortia. Here, we present our cohort/sample accrual – subjects (Feb-2016 to May-2019), aged 35–74 years were included. Controls from the endoscopy-sector and the cancer-prevention campaigns at ACCCC (May 2019), results and aims.

**Clinical aspects**

At the ACCCC ~ 130 GC-patients are diagnosed/year. Up-front surgery is performed in ~ 15% of early-disease cases. Patients with cT3/T4 tumors and N1,2,3 (~ 50%) usually receive perioperative chemotherapy and surgery (~ 70 gastrectomies/year), after staging laparoscopy. Most cases are discussed in weekly multidisciplinary tumor boards. Complete pathologic-response is seen in ~ 12% of patients. Median follow-up so far was 41 months, and the median survival since neoadjuvant chemotherapy was 73 months. Intention-to-treat analysis showed a 5-year overall survival of 65%. Clinical research includes the identification of surgical prognostic factors [1, 2] and the factors that impact outcome [3–5]. Patients are also invited to join the GE4GAC to investigate different aspects, such as the factors that contribute to GC development in Brazil, genes relevant for familial GC, predictors of neoadjuvant chemotherapy response and molecular variants that may indicate prognosis. Controls from the endoscopy-sector and the cancer-prevention campaign also participate (no-cancer) [6].

**Epidemiology**

We investigate associations between GC and demographic characteristics, dietary habits, and lifestyle primarily in subjects living in three geographic areas of Brazil: i) São Pãulo-SP (Southeast), ii) Belém-PA (North) and iii) Fortaleza-CE (Northeast). A total of 1121 subjects (Feb-2016 to May-2019), aged 35–74 years were interviewed, including GC-cases (N = 412; C16/ICD-O3) and two control groups including subjects recruited during the cancer-prevention campaigns at ACCCC (N = 153), or from the Endoscopy Department (no-cancer; N = 556).

**Basic and translational GC research**

Collected samples (N = 2856) include whole-blood, gastric-fluids, biopsies, saliva, and leukocytes, derived from > 400 cases+controls. These are used to investigate:

i) **Gastric Microbiota:** We investigate possible links between microbiota and GC, including tumor subtypes/location and neoadjuvant treatment/response. 16SrRNA sequencing, chosen due to elevated human:eubacteria ratios found in our samples, has been performed for ~ 460 samples, indicating ~ 50 bacteria present in biopsies and 2X-more for gastric-fluids. Reduced microbiota richness/diversity in cases was observed compared to controls. Shotgun-metagenomics and metatranscriptomics will be performed for selected samples, together with bacterial cultivation, to determine dead vs. alive bacteria. Virome and fungal populations will also be evaluated. qPCR EBV-analysis (N = 400) showed 12.7% EBV+ in GC-cases and 2.9% in controls. We recently showed a possible new mechanism of EBV-carcinogenesis where EBV-infection triggers APOBEC3 over-expression and an APOBEC-mutation signature [7].

ii) **Whole exome sequencing (WES) and RNA-Seq:** These will give comprehensive views of genome-wide alterations pertinent to our population and clinical interests, including immune infiltrates. We aim to have WES for ~ 400 patients and RNA-Seq mainly to support treatment-response studies.

iii) **Genomic ancestry:** Using a set of ~ 130,000 Ancestry Informative Markers [8] we found that the average cohort participant has a predominance of Mediterranean (50%), Northern-European (13.5%) and Southwest-Asia (12.5%) ancestries, followed by Sub-Saharan African (4.3%) and Native-American (3.8%) (unpublished). Genomic ancestry will be determined for all subjects and correlated against biological and demographic aspects, such as microbiota, diet, mutation profiles and treatment outcome.

iv) **Liquid-biopsies:** We evaluated the presence of cell-free tumor-derived mutations in gastric washes (GW) collected during endoscopy, comparing mutation levels with biopsies and plasma. Deep sequencing showed enhanced detection when plasma and GW are evaluated together. GW has been shown to carry mutations not found in biopsies, suggesting tumor heterogeneity/cancerization-field while providing a tool for monitoring treatment-response and disease-recurrence [9].

Other liquid-biopsies approaches investigated are Circulating Tumor Cells (CTCs) and Extracellular Vesicles...
(EVs). EVs-studies have been initiated in-vitro, as a means to study chemotherapy-resistance. Hundreds of patient-derived samples have been collected for further studies, including EV-RNA-Seq [10–12] and proteomics [13]. The prognostic-value of CTCs in GC was studied in 88 samples, collected from 55 GC-patients (before/after neoadjuvant-chemotherapy) [14]. A clinical trial of trastuzumab given to metastatic GC patients with HER2-negative tumor tissue but HER2 FISH-positive CTCs will start soon.

v) Hereditary GC (HGC): Germline pathogenic variants were found in CDH1, MUTYH, TP53, and ATM in 21% of HGC-suspect patients. Novel GC-predisposing genes are under study by WES.

**RedCap: a structured database**

Data from all enrolled subjects are securely kept in RedCap, a web-based application that currently holds the records from 401 controls and 440 GC-cases, including 1632 types of metadata, such as lifestyle (N = 845), diet (N = 629) and clinicopathological (N = 41) variables. The collection of massive amounts of data in a single unified database is a key aspect of GE4GAC, a project that is open for worldwide collaborations.

**Acknowledgements**

The authors acknowledge the support given by the Biobank of the A.C.Camargo Cancer Center and the associated research grants and fellowships provided by FAPESP and CAPES. ED-N, VRM, KJG and DMC are research fellows from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).

**Authors’ contributions**

Manuscript writing and GE4GAC coordination: ED-N. Epidemiology: MPC;_immunology: AMT, BSM, RV, AD, RB, REICD, JB, MNPS, JCS; EV-studies: VRM; DRC; Familial/early-onset disease: DMC, KMS, GTF; CTC-studies: LTDc, EAA, ABC, BCTF; Immunological studies: KJG, TW; Clinical/Pathological studies: F.K, WLClA, HCF, LGVC, SD, CALM, VHFJ, RR, LCLC; Endoscopy and sample collection: AGP, C2Z; Genomics/TFB, MGA, JMS, GEA, GPB, HCF, LFA, MSS, IKTMT, EE, DNN, ED-N; Microbiome: TF, MSS, GEA, AMT, DTS, LOM, BSM, AK, SD, PPA, IKTM, IITS, DNN. Research nurse: LLSA; Data manager: FIAT. All authors have read and expressed their consent to publish this letter.

**Funding**

This study was funded by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP), grants 14/26897–0, 18/50013–5; 18/14267–2; 16/11791–7. FAPESP had no roles in the design of the study and collection, analysis, and interpretation of the data or manuscript writing.

**Availability of data and materials**

Not applicable.

**Ethics approval and consent to participate**

The study presented here was approved by the institutional review board (Comitê de Ética em Pesquisa - CEPE) of the A.C. Camargo Cancer Center (protocol 2134/15), and all participants signed an approved informed consent form.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1Lab of Medical Genomics, A.C.Camargo Cancer Center, R. Tagua 440, Sao Paulo, SP 01508-010, Brazil. 2International Research Center, A.C.Camargo Cancer Center, R. Tagua 440, Sao Paulo, SP 01508-010, Brazil. 3Department CIBIO, University of Trento, Trento, Italy. 4Biochemistry Department, Chemistry Institute, Universidade de São Paulo, São Paulo, SP, Brazil. 5Lab. of Bioinformatics and Computational Biology, A.C.Camargo Cancer Center, R. Tagua 440, Sao Paulo, SP 01508-010, Brazil. 6Data Science group, International Research Center, A.C.Camargo Cancer Center, R. Tagua 440, Sao Paulo, SP 01508-010, Brazil. 7Department of Animal & Plant Sciences, University of Sheffield, Alfred Denny Building, Sheffield S10 2TN, UK. 8Instituto Alfa de Gastroenterologia, Hospital das Clínicas, Universidade Federal de Minas Gerais, Av. Alfredo Balena 110, Belo Horizonte, Minas Gerais 31301-100, Brazil. 9Instituto de Ciências Biológicas, Universidade Federal do Pará, Rua Augusto Correa, 01, Belém, PA 66075110, Brazil. 10Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Rua dos Mundurucus, 4487, Guamaré, Belém, Pará 66073-00, Brazil. 11Lab. de Genômica e Biologia Molecular, A.C.Camargo Cancer Center, R. Tagua 440, Sao Paulo, SP 01508-010, Brazil. 12Epidemiology and Statistics Group, A.C.Camargo Cancer Center, R. Tagua 440, Sao Paulo, SP 01508-010, Brazil. 13Laboratório de Biologia Molecular, Hospital Ophir Loyola, Belém, Brazil. 14Universidade Federal de Goiás, IPETEP – Instituto de Patologia Tropical e Saúde Pública, Rua 235 SN Setor Leste Universitário, Goiânia, Goiás, Brazil. 15Department of Abdominal Surgery, Hospital Araújo Jorge, Rua 239 181 Setor Leste Universitário, Goiânia, Goiás, Brazil. 16Instituto de Saúde Coletiva da Universidade Federal da Bahia, Rua Basílio da Gama 316, Canela, Salvador, Brazil. 17Instituto do Câncer do Ceará, Rua Papi Júnior, 1222 - Rodolfo Teófilo, Fortaleza, CE 60351-010, Brazil. 18Clinical Oncology Department, A.C. Camargo Cancer Center, R. Antônio Prudente, 211, São Paulo, SP 01509-010, Brazil. 19Department of Pathology, A.C. Camargo Cancer Center, R. Antônio Prudente, 211, São Paulo, SP 01509-010, Brazil. 20Endoscopy sector, A.C.Camargo Cancer Center, R. Antônio Prudente, 211, São Paulo, SP 01509-010, Brazil. 21Instituto Nacional de Enfermedades Neoplásicas, Av. Angamos 2520, 15038 Surquillo, Peru. 22Dept. of Biological and Medical Sciences, Faculty of Health and Life Sciences, Oxford Brookes University, Gipsy Lane, Headington, Oxford OX3 0BP, UK. 23Translational Immuno-oncology Group, A.C.Camargo Cancer Center, R. Tagua 440, Sao Paulo, SP 01508-010, Brazil. 24Tumor Biology and Biomarkers Group, A.C.Camargo Cancer Center, R. Tagua 440, Sao Paulo, SP 01508-010, Brazil. 25Department of Abdominal Surgery, A.C.Camargo Cancer Center, R. Antônio Prudente, 211, São Paulo, SP 01509-010, Brazil.

Received: 19 July 2019 Accepted: 3 September 2019

Published online: 22 October 2019

**References**

1. da Costa WL, Coimbra FJF, Ribeiro HSC, Diniz AL, de Godoy AL, de Farias IC, et al. Total gastrectomy for gastric cancer: an analysis of postoperative and long-term outcomes through time: results of 413 consecutive cases in a single cancer center. Ann Surg Oncol. 2015;22(3):750–7.
2. Coimbra FJF, da Costa WL, Ribeiro HSC, Diniz AL, de Godoy AL, de Farias IC, et al. Noncurative resection for gastric Cancer patients: who could benefit? : Determining prognostic factors for patient selection. Ann Surg Oncol. 2016;23(4):1212–9.
3. Costa WL, Coimbra FJ, Fogoraci RC, Ribeiro HSC, Diniz AL, Begnami MDF, et al. Adjuvant chemoradiotherapy after d2-lymphadenectomy for gastric cancer: the role of n-ratio in patient selection. Results of a single cancer center. Radiat Oncol. 2012;7:169.
4. Fava BEC, da Costa WL, Medeiros MIL, Sonagli M, de Castro Ribeiro HS, Diniz AL, et al. Neoadjuvant intraportal chemotherapy followed by
radical surgery and HIPEC in patients with very advanced gastric cancer and peritoneal metastases: report of an initial experience in a western single center. World J Surg Oncol. 2018;16(1):62.

5. Coimbra FJF, de Jesus VHF, Ribeiro HSC, Diniz AL, de Godoy AL, de Farias IC, et al. Impact of ypT, ypN, and adjuvant therapy on survival in gastric Cancer patients treated with perioperative chemotherapy and radical surgery. Ann Surg Oncol. 2019. Epub ahead of print.

6. GE4GAC group. Genomics and epidemiology for gastric adenocarcinomas. Appl Cancer Res. 2017;37:7.

7. Bobrovntchka I, Valieris R, Drummond RD, Lima JP, Freitas HC, Bartelli TF, et al. APOBEC-mediated DNA alterations: a possible new mechanism of carcinogenesis in EBV-positive gastric cancer. Int J Cancer. 2019 May 15. [Epub ahead of print]

8. Elhaik E, Tatarinova T, Chebotarev D, Piras IS, Maria Caló C, De Montis A, et al. Geographic population structure analysis of worldwide human populations infers their biogeographical origins. Nat Commun. 2014;5:3513.

9. Pizzi MP, Bartelli TF, Pelosof AG, Freitas HC, Begnami MD, de Abrantes LLS, et al. Identification of DNA mutations in gastric washes from gastric adenocarcinoma patients: possible implications for liquid biopsies and patient follow-up. Int J Cancer. 2019;145:1090–8.

10. Amorim MG, Valieris R, Drummond RD, Pizzi MP, Freitas VM, Sinigaglia-Coimbra R, et al. A total transcriptome profiling method for plasma-derived extracellular vesicles: applications for liquid biopsies. Sci Rep. 2017 31;7(1):14395.

11. Amorim MG, Bianco G, Valieris R, Tarciano E, Silva IT, Araújo LF, et al. The impact of HER2 overexpression on the mRNA and circRNA transcriptomes in two breast cell lines and their vesicles. Pharmacogenomics. 2019;20(7):493–502.

12. Bianco GP, Valieris R, Povoa LV, Araújo LF, Fernandez GR, Souza JES, et al. A comparison between SOLID 5500XL- and ion torrent PGM-derived miRNA expression profiles in two breast cell lines. Genet Mol Biol. 2019; in press.

13. Amorim M, Fernandez G, Oliveira P, Martins-de-Souza D, Diaz-Neto E, Nunes D. The overexpression of a single oncogene (ERBB2/HER2) alters the proteomic landscape of extracellular vesicles. Proteomics. 2014;14(12):1472–9.

14. Abdallah EA, Braun AC, Flores BCTCP, Senda L, Urvanegia AC, Calavara V, et al. The potential clinical implications of circulating tumor cells and circulating tumor microemboli in gastric Cancer. Oncologist. 2019.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.